All questionsSpecific populations: Skyrizi (risankizumab-rzaa), all indications4 questions · 1 sourceSpecific populationsIs Skyrizi safe during pregnancy?“Available pharmacovigilance and clinical trial data with risankizumab use in pregnant women are insufficient to establish a drug-associated risk of major birth defects, miscarriage or other adverse maternal or fetal outcomes. Although there are no data on risankizumab-rzaa, monoclonal antibodies can be actively transported across the placenta, and SKYRIZI may cause immunosuppression in the in utero-exposed infant.” (opens the source at this quote in a new tab)CopyFlag“Pregnancy Exposure Registry There is a pregnancy exposure registry that monitors outcomes in women who become pregnant while treated with SKYRIZI. Patients should be encouraged to enroll by calling 1-877-302-2161 or visiting http://glowpregnancyregistry.com.” (opens the source at this quote in a new tab)CopyFlagCan Skyrizi be used while breastfeeding?“There are no data on the presence of risankizumab-rzaa in human milk, the effects on the breastfed infant, or the effects on milk production. Endogenous maternal IgG and monoclonal antibodies are transferred in human milk. The effects of local gastrointestinal exposure and limited systemic exposure in the breastfed infant to risankizumab-rzaa are unknown. The developmental and health benefits of breastfeeding should be considered along with the mother's clinical need for SKYRIZI and any potential adverse effects on the breastfed infant from SKYRIZI or from the underlying maternal condition.” (opens the source at this quote in a new tab)CopyFlagIs Skyrizi safe and effective in adults 65 and older?“Of the 7,144 subjects exposed to SKYRIZI, a total of 685 were 65 years and older (243 subjects with plaque psoriasis, 246 subjects with psoriatic arthritis, 93 subjects with Crohn’s disease and 103 subjects with ulcerative colitis), and 73 subjects were 75 years and older. Clinical studies of SKYRIZI, within each indication, did not include sufficient numbers of subjects 65 years of age and older to determine whether they respond differently from younger adult subjects. No clinically meaningful differences in the pharmacokinetics of risankizumab-rzaa were observed based on age [see Clinical Pharmacology (12.3)].” (opens the source at this quote in a new tab)CopyFlagHas Skyrizi been studied in patients with kidney or liver impairment?“No studies have been conducted to determine the effect of renal or hepatic impairment on the pharmacokinetics of risankizumab-rzaa.” (opens the source at this quote in a new tab)CopyFlag